Richard Klausner
About Richard Klausner
Richard Klausner is the Chairman of the Board and Chief Scientist of Altos Labs, and has held numerous prominent roles in the biotechnology and health sectors, including leadership positions at Lyell Immunopharma, Juno Therapeutics, and the US National Cancer Institute.
Richard Klausner - Chairman of Altos Labs
Richard Klausner is the Chairman of the Board at Altos Labs, an organization focused on pioneering research and innovation. He also serves as the Founder and Chief Scientist of the company. His leadership role at Altos Labs involves steering groundbreaking scientific endeavors and fostering a culture of scientific excellence.
Founder of Lyell Immunopharma, Juno Therapeutics, and GRAIL
Richard Klausner has a notable track record as the founder of several biotech companies. He founded and serves as Chairman of Lyell Immunopharma, Inc. He is also a founder and current director of Juno Therapeutics and GRAIL. These companies are involved in cutting-edge therapeutic developments and innovations in biotechnology, further showcasing Klausner’s commitment to advancing medical science.
Former Executive at Illumina and Gates Foundation
Richard Klausner previously held executive positions at major organizations. At Illumina Corporation, he served as Senior Vice President, Chief Medical Officer, and Chief Opportunity Officer. Additionally, he was the Executive Director for Global Health at the Bill and Melinda Gates Foundation. These roles involved high-level strategic oversight and contributions to global health and genomic advancements.
Director of the US National Cancer Institute
Appointed by Presidents Clinton and Bush, Richard Klausner served as the eleventh Director of the US National Cancer Institute from 1995 to 2001. During his tenure, he played a critical role in steering the institute's research initiatives and policies aimed at combating cancer.
Senior Advisory Roles to Multiple Governments
Richard Klausner has also provided his expertise in senior advisory roles to various governments, including those of the US, Norway, Qatar, and India. His advisement has likely influenced public health policies and scientific initiatives in these nations, contributing to global health improvements.